Evidence-Based Global Impact

TransformingHealthcare

Genetic testing is shifting healthcare from reactive treatment to personalized prevention, saving lives and reducing costs worldwide.

$50B+
Market by 2033
30%
Fewer ADRs
94%
Survival Rate
419
Lives Saved/Year
GLOBAL MARKET GROWTH

A $50 Billion Industry by 2033

The genetic testing market is projected to grow from $11.7B in 2024 to nearly $50‑91B by 2033‑34, driven by the shift toward proactive prevention.

Regional Market Share 2024

North America
Share: 45.4%12.3% CAGR
Europe
Share: 28.2%14.1% CAGR
Asia Pacific
Share: 18.7%25.7% CAGR
Rest of World
Share: 7.7%18.9% CAGR
Asia‑Pacific is the fastest growing region at 25.7% CAGR

Next‑Gen Sequencing (NGS)

Holds 49.3% revenue share in 2024, enabling precise multi‑gene analysis at lower costs.

Leading Technology
AI‑Driven Analysis

Fastest growing segment in software & services

China Initiative

1M+ genomes to be sequenced by 2030

CLINICAL EVIDENCE

Research‑Backed Results

Real data from clinical trials and global studies proving the life‑saving impact of genetic testing.

11.3%

5-Year Survival Rate

For BRCA carriers with pre-diagnosis awareness vs 78% without

9.6%

Early Stage Detection

Cases caught at Stage 0-1 with genetic screening

1.2 yrs

Life Expectancy Gain

For BRCA1 carriers with preventive interventions

Women who know their BRCA status before diagnosis have dramatically better outcomes. 64% of breast cancers in known carriers are detected by MRI at treatable stages.

Source: Clinical Oncology Research 2024
SAVING LIVES

The Human Impact

Every statistic represents real people whose lives have been transformed through preventive genetic testing.

80%

Cardiovascular Mortality Reduction

With early statin therapy for familial hypercholesterolemia

50%

Fewer Hospitalizations

For patients with PGx‑guided prescriptions

73→28%

Chemo Toxicity Reduced

DPYD gene testing before chemotherapy

18%

Pediatric Mortality Reduction

In anthracycline‑induced cardiotoxicity

300+

FDA Drug Labels with Genetic Guidance

$2-4K/yr

Cost Savings per Patient (Antidepressants)

71%

PGx Studies Showing Cost‑Effectiveness

HEREDITARY CANCER

BRCA Testing Saves Lives

Early knowledge of BRCA status dramatically improves survival outcomes and enables life‑saving preventive measures.

Lifetime Cancer Risk

Breast Cancer
BRCA Carriers
45-85%
General Population
12%
Ovarian Cancer (BRCA1)
BRCA Carriers
39-58%
General Population
1.1%
Ovarian Cancer (BRCA2)
BRCA Carriers
13-29%
General Population
1.1%

Life Expectancy Gains

Preventive Mastectomy + Oophorectomy (BRCA1)

10.3 years

Preventive Mastectomy + Oophorectomy (BRCA2)

4.4 years

Annual MRI + Mammography Screening (BRCA1)

2-9.9 years

Oophorectomy at Age 40 (BRCA1)

15% survival gain by 70

The Power of Early Knowledge

Women aware of their BRCA status before diagnosis have a 94% five‑year survival rate compared to 78% for those who learn after diagnosis. 86% of cases are caught at Stage 0‑1 with genetic screening, versus only 39% without.

FUTURE OUTLOOK

The Future of Preventive Healthcare

Projections for 2025‑2034 show exponential growth in genetic testing adoption worldwide.

Market Value 2033‑34

$49.7B - $91.3B

Projected global market size depending on sector definitions

Growth Rate (CAGR)

9.7% - 22.6%

Compound annual growth rate through 2034

Fastest Growing Segment

AI‑Driven Analysis

Software & services powered by artificial intelligence

Be Part of the Prevention Revolution

Join millions worldwide who are taking control of their health through genetic insights. Early detection saves lives.

Explore Our TestsTalk to an Expert

Data sources: FDA Guidelines 2024, PREPARE Trial, Clinical Oncology Research, Global Rare Disease Study